Visium Asset Management’s Edwards Lifesciences EW Stock Holding History

Visium Asset Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-375,000	Closed	-$11M	–	395
2016 Q1	$11M	Buy	+375,000	New	+$10.3M	0.19%	139
2015 Q4	–	Sell	-150,000	Closed	-$3.55M	–	671
2015 Q3	$3.55M	Buy	+150,000	New	+$3.62M	0.05%	352
2014 Q1	–	Sell	-12,036	Closed	-$672K	–	916
2013 Q4	$672K	Buy	+12,036	New	+$136K	0.01%	530

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Visium Asset Management's EW Position: Q2 2016 in Review

Visium Asset Management sold out of Edwards Lifesciences (EW) in Q2 2016, closing a stake of 137,778 shares — an estimated $4.05M sold.

Visium Asset Management first reported a position in EW in Q3 2013 and held it in 11 quarters. The position peaked at $55.2M in Q2 2015. 693 funds tracked by Wall St. Rank hold EW as of Q2 2016.

Visium Asset Management reported no remaining Edwards Lifesciences position as of Q2 2016 after selling out during the quarter.
Visium Asset Management sold 137,778 Edwards Lifesciences shares in Q2 2016, an estimated $4.05M.
Visium Asset Management first reported a position in Edwards Lifesciences in Q3 2013 and held it in 11 quarters.
Visium Asset Management's Edwards Lifesciences position peaked at $55.2M in Q2 2015.
693 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2016.

Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.